Business Wire

THALES

Share
Thales Enables Teradata Vantage Customers to Protect Data at Rest With Simplicity, Speed and Scale

Thales today announced a new high-performance data security solution for Teradata customers using the Vantage platform for data and analytics. By providing users with a totally transparent and scalable encryption solution to protect data at rest in any environment, the Thales Transparent Encryption solutions enable Teradata Vantage customers to better meet compliance and privacy regulations through encryption, access controls and data access audit logging.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005043/en/

Easily deployed across files and systems, this solution enables data at rest to be quickly encrypted within the Vantage platform. Since it is “transparent”, it is simple to deploy because there are no application development or database integration changes required. The cost-effective solution removes data breach risks and supports compliance initiatives while saving organisations months on the deployment of data protection for a Teradata environment.

Effective Access Policy Management at Scale

Thales’ Transparent Encryption is completely invisible to Vantage users and administrators as long as they are authorised to access the databases and system files they won’t know that solution is protecting your business. However, processes and actions from unauthorised users are immediately stopped and logged. The solution can be flexibly deployed across physical, virtual and cloud environments, giving organisations the ability to implement granular access policies that allow administrators to access infrastructure and systems without ever being able to see sensitive data in clear text.

The solution is designed to meet the high-scale and performance requirements of Vantage deployments on-premises, in clouds and hybrid, which can be several hundred terabytes to many petabytes in size and contain highly sensitive and regulated data and subsequently subject to privacy regulations (e.g., GDPR, CCPA, etc.). The scalable solution provides little overhead, from encryption and decryption activities, letting users robustly secure data and retain critical I/O and storage efficiencies.

“We’re pleased to have worked with the Teradata team to expand the Thales offering to include the transparent encryption solutions for Teradata. Our existing joint customers will simply expand their data security platform investment to include their Vantage environment. They will find that the policies for encryption, privileged user access and the additional security intelligence logs to further enhance their visibility are entirely familiar. New customers will be taking their first steps in unifying all their data security requirements and use cases on one easy to use, scalable and high-performance platform. The Thales solution complements the rich set of controls in the Vantage environment, ensuring that deployments meet the toughest regulatory audit scrutiny and protects a company’s most valuable data,” said Todd Moore, Senior Vice President, Encryption Solutions at Thales .

Jay Irwin JD, Director of Teradata Center for Enterprise Security added: "Teradata’s customer base is comprised of some of the largest and most data-centric companies on the planet. Security at scale is vital to this clientele, which makes Thales’ solution a particularly good fit for enabling Teradata's best-in-industry cloud security to be even more robust. With the application of Thales transparent encryption solutions, we provide a layered defense that protects customer data on-premises, in the cloud and in hybrid environments – all deployment types that our customers use today.”

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Market page

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye